Incorporating Insulin Growth Factor-1 into Regenerative and Personalized Medicine for Cardiovascular Disease: A Systematic Review

<jats:sec>
<jats:title>Background:</jats:title>
<jats:p>Cardiovascular disease (CVD) is one of the world’s leading causes of increased
morbidity and mortality. Current interventions for CVD, including percutaneous transluminal coronary
angioplasty (PTCA) and coronary artery bypass grafting (CABG), carry certain risks and complications,
which may also affect the patient’s quality of life. It is important to minimize those risks and complications
while speeding up the recovery. Insulin Growth Factor-1 (IGF-1) is a growth factor responsible for
cellular migration, proliferation, differentiation, and angiogenesis, which supports cardiovascular regeneration.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Methods:</jats:title>
<jats:p>In light of the current trend of regenerative medicine, the present review aims to pool data relating
to the incorporation of IGF-1 in regenerative medicine and provide input on the current research gaps
and concerns arising on translating this approach from benchwork into clinical settings.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Results:</jats:title>
<jats:p>Using the keywords IGF-1 ‘OR’ Insulin Growth Factor 1 ‘AND’ Mesenchymal Stem Cells
‘AND’ Tissue Healing from 2009 to 2020, we identified 160 and 52 from Medline and PubMed, screening
out 202 articles due to non-fulfilment of the inclusion criteria.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Conclusion:</jats:title>
<jats:p>Incorporating IGF-1 into regenerative and personalized medicine may be promising for
treating CVD; however, the concerns include the role of IGF-1 in inducing cancer growth and its ability
to migrate to the specific site of injury, especially for those who present with multiple pathologies should
be addressed prior to its translation from bench work into clinical settings.</jats:p>
</jats:sec>